Please wait while the formulary information is being retrieved.
MEPRON (ATOVAQUONE)
- Pneumocystis jiroveci pneumonia prevention
- Pneumocystis jirovecii pneumonia
750 mg/5 mL oral suspension
- 5 milliliters (750 mg) by oral route 2 times per day with meals
750 mg/5 mL oral suspension
- 5 milliliters (750 mg) by oral route 2 times per day with meals
Pneumocystis jiroveci pneumonia prevention
- 10 milliliters (1,500 mg) by oral route once daily with a meal
Pneumocystis jirovecii pneumonia
- 5 milliliters (750 mg) by oral route 2 times per day with meals for 21 days
- 5 milliliters (750 mg) by oral route 2 times per day with meals
- artemether-lumefantrine
- Coartem
Contraindicated
- First-mary's Mouthwash
- metoclopramide HCl
- Metozolv Odt
- nystatin-TCN-HC-diphenhydramin
- Reglan
- tetracycline
Severe
Moderate
- isoniazid-rifamp-pyrazinamide
- Mycobutin
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- None
Contraindicated
- Malabsorption states
Severe
Moderate
- Severe hepatic disease
MEPRON (ATOVAQUONE)
- Pneumocystis jiroveci pneumonia prevention
- Pneumocystis jirovecii pneumonia
- None
- Cough
- Diarrhea
- Fever
- Headache disorder
- Insomnia
- Nausea
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Dizziness
- Hyperhidrosis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute renal failure
- Angioedema
- Bronchospastic pulmonary disease
- Disorder of cornea
- Erythema multiforme
- Hepatic failure
- Hepatitis
- Methemoglobinemia
- Pancreatitis
- Stevens-johnson syndrome
- Throat constriction
- Thrombocytopenic disorder
- Urticaria
Less Severe
- Depression
- General weakness
- Myalgias
- Pruritus of skin
- Sinusitis
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Atovaquone
No evidence of safety and efficacy in pediatrics age < 13 years.
- 1 Day – 13 Years
- No evidence of safety and efficacy in pediatrics age < 13 years.
Atovaquone
- Severity Level:
2
- Additional Notes: Insufficient data available; consider maternal benefit vs potential fetal risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Atovaquone
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Pneumocystis jiroveci pneumonia prevention | |
| B59 | Pneumocystosis |
| Pneumocystis jirovecii pneumonia | |
| B59 | Pneumocystosis |
| 0-9 | A-Z |
|---|---|
| B59 | Pneumocystosis |
| B59 | Pneumocystosis |
Formulary Reference Tool